Y-4 to Treat the Postherpetic Neuralgia

NCT07275762

Status	RECRUITING
Phase	Phase 2
Sponsor	Neurodawn Pharmaceutical Co., Ltd.
Enrollment	160 participants

Key Eligibility Criteria

Inclusion (2)

- \- 1. Able to understand and voluntarily sign the informed consent form. 2. Age e 18 years, any gender. 3. Diagnosed with PHN, meaning pain persists for more than one month after the acute shingles rash has healed.
- \. VAS score in SF-MPQ e 40 mm of the last 24 hours during screening.

Exclusion (22)

- \. Known previous allergy to the investigational products, rescue medication ingredients, other chemically similar drugs, or excipients.
- \. During screening, individuals who have been clearly diagnosed with peripheral neuropathy or pain unrelated to PHN (including but not limited to those caused by cerebrovascular disease, Guillain-Barré syndrome, cervical or lumbar spine disorders, osteoarticular or tendon lesions, chronic kidney disease or uremia, thyroid disease, intracranial tumors, trauma, etc.) and are judged by the investigator to potentially confound the assessment of PHN.
- \. During screen, suffer from a systemic disease that, in the opinion of the investigator, may affect the patient's participation in the study or affect the evaluation of the efficacy of PHN, including but not limited to:
- Severe cardiopulmonary diseases, such as unstable angina, myocardial infarction, severe arrhythmia within 6 months prior to screening, NYHA cardiac function classification of grade III\~IV at screening, hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg at screening), recurrent asthma attacks, etc.;
- Chronic digestive diseases, such as liver fibrosis, chronic active hepatitis, peptic ulcer, etc.;

... and 17 more (see full listing online)

Locations (1 total)

Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China